Emcure receives US FDA Form 483 with 7 observations following inspection – Business Upturn
Emcure Pharmaceuticals has been issued a Form 483 by the United States Food and Drug Administration (US FDA) following a current Good Manufacturing Practices (cGMP) inspection at its formulations facility in Sanand, Ahmedabad. The inspection, conducted from 6th May 2026 to 15th May 2026, resulted in seven procedural observations. The company has stated that it is addressing these observations comprehensively…
Key Insights
- This topic is currently trending
- Experts are closely monitoring developments
- It may impact future decisions
